The rules governing the modern regulation of compounders were enshrined in the Drug Quality and Security Act (DQSA), signed into law in 2013
This compounded product has not been reviewed, approved, or evaluated by the Food and Drug Administration for safety and effectiveness
That means the level of risk may be different for the general population
Timing after that depends on safety screening, treatment choice, and pharmacy fulfillment
Participants were randomized to placebo or retatrutide at 1 mg, 4 mg (dose-escalation), 4 mg (no escalation), 8 mg (escalation), 8 mg (no escalation), or 12 mg (escalation) for 48 weeks, following a slow titration protocol